Scinai Immunotherapeutics Ltd. Sponsored Adr ( (SCNI) ) has released its Q3 earnings. Here is a breakdown of the information Scinai Immunotherapeutics Ltd. Sponsored Adr presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Scinai Immunotherapeutics Ltd. is a biopharmaceutical company focusing on innovative inflammation and immunology therapeutics and operating a boutique contract development and manufacturing organization (CDMO) business. The company recently reported its financial results for the first nine months of 2025, highlighting significant growth in its CDMO operations and advancements in its NanoAbs pipeline.
For the nine months ending September 30, 2025, Scinai reported revenues of $1,049 thousand, a substantial increase from $452 thousand in the same period in 2024. This growth was driven by the expansion of Scinai Bioservices, including contributions from its U.S. subsidiary. However, the company faced a net loss of $6,244 thousand, contrasting with a net profit of $7,026 thousand in the previous year, largely due to the absence of financial income from loan conversion recorded in 2024.
Scinai’s CDMO business, Scinai Bioservices, is gaining traction in North America, contributing $502 thousand in revenues. The company also secured a grant from the Israel Innovation Authority to enhance its manufacturing capabilities with an advanced sterile fill-and-finish system, expected to be operational by Q2 2026. In its R&D division, Scinai is advancing its NanoAbs pipeline, focusing on high-value IL-17 programs and seeking strategic partnerships for co-development or licensing.
Looking ahead, Scinai remains focused on expanding its operational capabilities and exploring strategic paths for its R&D programs. Despite the setback in grant approval for the PC111 program, the company is evaluating alternative funding routes and remains committed to advancing its NanoAbs pipeline and creating long-term value for its stakeholders.